FINANCIAL ASPECTS. The cost of this TRIAL has been initially budgeted at EUROS, not including VAT, (€ ) (hereinafter, the TRIAL Budget), in accordance with the provisions of the Financial Memorandum for the TRIALS (Schedule I), which specifies all their financial aspects. This amount does not, in any case whatsoever, include an obligation or inducement for the HOSPITAL, the FOUNDATION, and/or the LEAD INVESTIGATOR to recommend, prescribe, buy, use or arrange the use of any of the SPONSOR’s products. To request an invoice, contact: xxxxxxxxxxx.xxxx@xxxxx.xxxxxx.xxx In addition, upon signature of this contract, the SPONSOR/CRO (choose as appropriate) will pay the amount of 4,000/3,000 Euros, in a one-time, non-refundable payment, as administrative and contractual management costs. This payment will include expenses for CEIm evaluation, relevant amendments, contract management administration and addendum to the contract. This payment will include expenses for contract management administrative procedures and addendum to the contract. If the fiscal details of this invoice are different from those detailed for visitor invoices in clause 5.4., please indicate them below: Invoices will be issued to: Name: CIF/VAT number / Tax ID Number: Domicile / Registered Address: Invoices will be sent for processing to the following e-mail: The amount to be paid by the SPONSOR/CRO (choose as appropiate) during performance of the TRIALS will be calculated by applying Schedule I and must be paid to the FOUNDATION in the payments set out below: The TRIALS budget will be paid, at least, every six months in accordance with the details in the amounts table by visit and subject signed up included in Schedule I, until the total amount of the Budget has been paid. For that purpose, SPONSOR/CRO (choose as appropiate) and the LEAD INVESTIGATOR will report to the FOUNDATION every six months. These payments are considered to be payments on account, pending payment of the definitive total for the TRIALS. The definitive total to be paid by the SPONSOR/CRO (choose as appropiate) for performing the TRIALS will be calculated based on the work effectively carried out to perform the TRIALS (hereinafter, the Definitive Total). The Definitive Total will be calculated as follows: Within a maximum of three (3) months after termination of the TRIALS at the HOSPITAL, the SPONSOR/CRO (choose as appropiate) SPONSOR/CRO (choose as appropriate) and the LEAD INVESTIGATOR will notify the FOUNDATION in writing of the total number of: (1) subjects signed up and assessed, (2) visits effectively paid, (3) incidents occurring, and (4) any hospital test, analysis, exploration, appointment or stay of an extraordinary nature which may have occurred, whether or not they are reflected in the Financial Memorandum (Schedule I). As soon as possible after the information referred to in the previous paragraph has been notified, the FOUNDATION will calculate, issue and notify the SPONSOR/CRO (choose as appropiate), in a final invoice for the trials, the amount of the definitive total and, if necessary, claim the amounts pending payment, which must be paid within one (1) month, without the need for a subsequent request. Once the final payment is made, it will be understood that the SPONSOR’s financial obligations have concluded. All payments must be made on submission of the invoice, to which VAT will be added in accordance with the applicable law on the date it is issued on, in the name of the SPONSOR or the ENTITY/PERSON IN CHARGE OF FINANCIAL ASPECTS (invoicing details) Name: CIF/VAT number / Tax ID Number: Domicile / Registered Address: Invoices will be sent for processing to the following e-mail: The SPONSOR/CRO must communicate by email to FIBHU12O the total amount that must be invoiced for the visits that have been made, detailing the breakdown of each of these visits and procedures detailed in the Economic Report (ANNEX_I). For this, must send an e-mail to xxxxxxxxxxx.xxxx@xxxxx.xxxxxx.xxx Payments to the FOUNDATION will be made by bank transfer, with charges payable by the sender, to: Holder/Beneficiary: Fundación para la Investigación Biomédica del Hospital Universitario 12 de octubre. Bank: Caixabank, S.A. Address: Xxxxx xx xx Xxxxxxxxxx, 00 0x 00000-Xxxxxx Account Nº/IBAN: XX00 0000 0000 0000 0000 0000 SWIFT CODE: CAIXE SBBxxx VAT number /Tax ID CODE: X-00000000 Payments made by the SPONSOR/CRO (choose as appropiate) to the FOUNDATION will be full settlements for the former, with the FOUNDATION being responsible for payment the amounts that, as appropriate, are payable to the TRIALS researchers. The PARTIES agree that, if the HOSPITAL lacks the necessary equipment for adequate performance of the TRIALS, the SPONSOR will provide the HOSPITAL with it, free-of-charge and assigning its use, either directly or via a third party. Furthermore, the SPONSOR will pay the cost, and arrange the supply, installation, maintenance, calibration and removal of the equipment, and training personnel in operating it, if necessary. The HOSPITAL, the FOUNDATION and the LEAD INVESTIGATOR will, in no case, be liable for its maintenance or its eventual loss. The equipment will consist of the following components: The Equipment will remain the property of the SPONSOR, or a third party, and will carry the relevant identification to show this. The Equipment may only be used to perform the TRIAL and, when it has ended, will be returned to the SPONSOR, or a third party, at no cost to the HOSPITAL or the FOUNDATION. When the LEAD INVESTIGATOR receives a request for return, they will make the Equipment available to the SPONSOR, or the third party appointed by it to collect it. On termination of the TRIALS, the SPONSOR may assign the Equipment to the HOSPITAL free-of-charge, for which purpose such documents as are necessary will be formalised. In the event that additional needs for equipment are detected during performance of the TRIALS, subsequent to the signature of this contract, the PARTIES must sign an addendum including the equipment made available, respecting the terms and conditions set out in the previous paragraphs.
Appears in 2 contracts
FINANCIAL ASPECTS. The cost of this TRIAL has been initially budgeted at EUROS, not including VAT, __________EUROS (______€ ) (hereinafterTRIAL budget, from now on). This cost has been determined by applying a cost of _______ EUROS (____ €) per subject to be evaluated, as established by the Economic Memorandum of the TRIAL Budget), in accordance with the provisions of the Financial Memorandum for the TRIALS (Schedule IAnnex 1), which specifies all their financial economic aspects. This amount does not, in not cover or provide for any case whatsoever, include an obligation or inducement commitment for the HOSPITAL, the FOUNDATION, Foundation and/or the LEAD PRINCIPAL INVESTIGATOR to recommend, endorse, prescribe, buypurchase, use or arrange agree the use of any of the SPONSOR’s products. To request an invoice, contact: xxxxxxxxxxx.xxxx@xxxxx.xxxxxx.xxx In addition, upon signature The study budget includes a unique payment of this TWO THOUSAND EUROS (2.000 €) for management of the present contract, the SPONSOR/CRO (choose as appropriate) will pay the amount of 4,000/3,000 Euros, in a one-time, non-refundable payment, as administrative and contractual management costs. This payment will include expenses for CEIm evaluation, relevant amendments, contract management administration and addendum according to the contractestablished in the Study Budget (Annex I). This payment will include expenses for contract management administrative procedures and addendum to the contract. If the fiscal details of this invoice are different from those detailed for visitor invoices in clause 5.4., please indicate them below: Invoices will be issued to: Name: CIF/VAT number / Tax ID Number: Domicile / Registered Address: Invoices will be sent for processing to the following e-mail: The amount sum to be paid by the SPONSORSPONSOR/CRO (choose as appropiate) during performance during the implementation of the TRIALS will CLINICAL TRIAL shall be calculated by applying set according to the specifications of Schedule I 1, and must shall be paid to the FOUNDATION as detailed below: TWO THOUSAND EUROS (2.000€), non refundable, will be paid at contract signature, in the payments set out below: concept of contract management. The TRIALS remainder of the CLINICAL TRIAL budget will shall be paid, at leastleast each semester, every six months in accordance with the details as detailed in the amounts table by of cost per visit and subject signed up recruited patient included in as Schedule I, 1 until the total amount cost of the Budget has been paidbudget is fully paid off. For that purpose, SPONSOR/CRO (choose as appropiate) The SPONSOR and the LEAD PRINCIPAL INVESTIGATOR will shall report to the FOUNDATION every six monthson a biyearly basis. These payments are instalments shall be considered as partial payments, subject to be payments on account, pending payment the settlement of the definitive final total expenses of the CLINICAL TRIAL. The final contribution of the SPONSOR for the TRIALS. The definitive total to implementation of the CLINICAL TRIAL shall be paid determined by the SPONSOR/CRO (choose as appropiate) for performing the TRIALS will be calculated based on the work effectively activities actually carried out to perform while conducting the TRIALS CLINICAL TRIAL (hereinafter, the Definitive Total‘Final cost’). The Definitive Total will Final cost shall be calculated estimated as follows: Within a maximum of three (3) months after termination from completion of the TRIALS TRIAL at the HOSPITAL, the SPONSOR/CRO (choose as appropiate) SPONSOR/CRO (choose as appropriate) and the LEAD PRINCIPAL INVESTIGATOR will notify shall report in writing to the FOUNDATION in writing of the total number of: of (1) subjects signed up recruited and assessedevaluated subjects, (2) visits effectively paidactual number of visits, (3) incidents occurringresulting incidents, and as well as (4) any tests, analyses, examinations, consultations or hospital test, analysis, exploration, appointment or stay stays of an extraordinary special nature which may that might have occurred, whether or not they are reflected included in the Financial Memorandum Schedule (Schedule I1). As soon as possible after the information referred to in of the previous paragraph point has been notified, the FOUNDATION will calculate, issue shall calculate and notify the SPONSORSPONSOR/CRO (choose as appropiate), in a the final invoice for the trials, the amount payment of the definitive total andCLINICAL TRIAL, as well as the outstanding sums, if necessary, claim the amounts pending paymentany, which must shall be paid within one (1) month, month without the need for a subsequent requestfurther requirement. Once This settlement of the final payment is made, it will shall be understood that regarded to all effects as due compliance by the SPONSOR’s SPONSOR of his financial obligations have concludedobligations. All payments must shall be made on submission upon the presentation of an invoice; the invoicecorresponding VAT shall be included as per current legislation at the time of payment, to which VAT will be added in accordance with the applicable law on the date it is issued on, in at the name of the SPONSOR or the ENTITY/PERSON IN CHARGE OF FINANCIAL ASPECTS (invoicing details) Nameonly legalized subsidiary in Spain). Invoices will be issued to the sponsor: CIF/VAT _________ (NOTE: Invoices will be issued to the sponsor, unless otherwise expressly stated that the invoices are issued to legalized sponsor linked subsidiary in Spain, whose data should be included in this clause). Invoices issued to the sponsor shall be provided by the following payer whose details are as follows: _________________ (NOTE: If you need to include an order number / Tax ID Number: Domicile / Registered Address: or purchase order invoices must indicate, and the procedure to be applied by the Foundation). Invoices will be sent for processing to the following e-mailaddress management: The SPONSOR/CRO must communicate by email to FIBHU12O the total amount that must be invoiced for the visits that have been made, detailing the breakdown of each of these visits and procedures detailed in the Economic Report (ANNEX_I). For this, must send an e-mail to xxxxxxxxxxx.xxxx@xxxxx.xxxxxx.xxx Payments ________ All payments to the FOUNDATION will Foundation shall be made by bank transfer, transfer (with charges payable bank fees being paid by the sender, payer) to: Holder/BeneficiaryName: Fundación para la Investigación Biomédica del Hospital Universitario 12 de octubre. BankXxxxxxxx Xxxxxxx Banking Entity: Caixabank, S.A. AddressBankia Account number: Xxxxx xx xx Xxxxxxxxxx, 00 0x 00000-Xxxxxx Account Nº/IBAN2038 1163 13 6000526076 IBAN: XX00 0000 0000 0000 0000 0000 SWIFT CODEES 86 2038 1163 13 6000526076 SWIFT: CAIXE SBBxxx VAT number /Tax ID CODECAHMESMMXXX CIF: X-00000000 Payments made by the SPONSOR/CRO (choose as appropiate) to the FOUNDATION will be full settlements for the former, with the FOUNDATION being responsible for payment the amounts that, as appropriate, are payable to the TRIALS researchers. The PARTIES agree that, if the HOSPITAL lacks the necessary equipment for adequate performance of the TRIALS, the SPONSOR will provide the HOSPITAL with it, free-of-charge and assigning its use, either directly or via a third party. Furthermore, the SPONSOR will pay the cost, and arrange the supply, installation, maintenance, calibration and removal of the equipment, and training personnel in operating it, if necessary. The HOSPITAL, the FOUNDATION and the LEAD INVESTIGATOR will, in no case, be liable for its maintenance or its eventual loss. The equipment will consist of the following components: The Equipment will remain the property of the SPONSOR, or a third party, and will carry the relevant identification to show this. The Equipment may only be used to perform the TRIAL and, when it has ended, will be returned to the SPONSOR, or a third party, at no cost to the HOSPITAL or the FOUNDATION. When the LEAD INVESTIGATOR receives a request for return, they will make the Equipment available to the SPONSOR, or the third party appointed by it to collect it. On termination of the TRIALS, the SPONSOR may assign the Equipment to the HOSPITAL free-of-charge, for which purpose such documents as are necessary will be formalised. In the event that additional needs for equipment are detected during performance of the TRIALS, subsequent to the signature of this contract, the PARTIES must sign an addendum including the equipment made available, respecting the terms and conditions set out in the previous paragraphs.X-00000000
Appears in 1 contract
Samples: www.iisgm.com
FINANCIAL ASPECTS. The cost of this TRIAL has been initially budgeted at EUROS, not including VAT, __________EUROS (______€ ) (hereinafterTRIAL budget, from now on) of which 78% was for the RESEARCH TEAM and 22% indirect costs for the FOUNDATION. This cost has been determined by applying a cost of _______ EUROS (____ €) per subject to be evaluated, as established by the Economic Memorandum of the TRIAL Budget), in accordance with the provisions of the Financial Memorandum for the TRIALS (Schedule IAnnex 1), which specifies all their financial economic aspects. This amount does not, in not cover or provide for any case whatsoever, include an obligation or inducement commitment for the HOSPITAL, the FOUNDATION, Foundation and/or the LEAD PRINCIPAL INVESTIGATOR to recommend, endorse, prescribe, buypurchase, use or arrange agree the use of any of the SPONSOR’s products. To request an invoiceThe study budget includes a unique payment, contact: xxxxxxxxxxx.xxxx@xxxxx.xxxxxx.xxx In addition, upon signature regardless of this the number of patients included in the trial. of XXXXX EUROS (XXXX€) for the Pharmacy Service and a unique payment of ONE THOUSAND FIVE HUNDRED EUROS (1.500 €) for management of the present contract, the SPONSOR/CRO (choose as appropriate) will pay the amount of 4,000/3,000 Euros, in a one-time, non-refundable payment, as administrative and contractual management costs. This payment will include expenses for CEIm evaluation, relevant amendments, contract management administration and addendum according to the contractestablished in the Study Budget (Annex I). This payment will include expenses for contract management administrative procedures and addendum to the contract. If the fiscal details of this invoice are different from those detailed for visitor invoices in clause 5.4., please indicate them below: Invoices will be issued to: Name: CIF/VAT number / Tax ID Number: Domicile / Registered Address: Invoices will be sent for processing to the following e-mail: The amount sum to be paid by the SPONSORSPONSOR/CRO (choose as appropiate) during performance during the implementation of the TRIALS will CLINICAL TRIAL shall be calculated by applying set according to the specifications of Schedule I 1, and must shall be paid to the FOUNDATION as detailed below: XXXXXX EUROS (XXXX€), non refundable, will be paid at contract signature, in the payments set out belowconcept of: A unique payment of ____________________ (000€), regardless of the number of patients included in the trial for the Pharmacy Service. IF APPLICABLE A unique payment of __________________ (1.500€) to the FOUNDATION, in concept of contract management. The TRIALS remainder of the CLINICAL TRIAL budget will shall be paid, at leastleast each semester, every six months in accordance with the details as detailed in the amounts table by of cost per visit and subject signed up recruited patient included in as Schedule I, 1 until the total amount cost of the Budget has been paidbudget is fully paid off. For that purpose, SPONSOR/CRO (choose as appropiate) The SPONSOR and the LEAD PRINCIPAL INVESTIGATOR will shall report to the FOUNDATION every six monthson a biyearly basis. These payments are instalments shall be considered as partial payments, subject to be payments on account, pending payment the settlement of the definitive final total expenses of the CLINICAL TRIAL. The final contribution of the SPONSOR for the TRIALS. The definitive total to implementation of the CLINICAL TRIAL shall be paid determined by the SPONSOR/CRO (choose as appropiate) for performing the TRIALS will be calculated based on the work effectively activities actually carried out to perform while conducting the TRIALS CLINICAL TRIAL (hereinafter, the Definitive Total‘Final cost’). The Definitive Total will Final cost shall be calculated estimated as follows: Within a maximum of three (3) months after termination from completion of the TRIALS TRIAL at the HOSPITAL, the SPONSOR/CRO (choose as appropiate) SPONSOR/CRO (choose as appropriate) and the LEAD PRINCIPAL INVESTIGATOR will notify shall report in writing to the FOUNDATION in writing of the total number of: of (1) subjects signed up recruited and assessedevaluated subjects, (2) visits effectively paidactual number of visits, (3) incidents occurringresulting incidents, and as well as (4) any tests, analyses, examinations, consultations or hospital test, analysis, exploration, appointment or stay stays of an extraordinary special nature which may that might have occurred, whether or not they are reflected included in the Financial Memorandum Schedule (Schedule I1). As soon as possible after the information referred to in of the previous paragraph point has been notified, the FOUNDATION will calculate, issue shall calculate and notify the SPONSORSPONSOR/CRO (choose as appropiate), in a the final invoice for the trials, the amount payment of the definitive total andCLINICAL TRIAL, as well as the outstanding sums, if necessary, claim the amounts pending paymentany, which must shall be paid within one (1) month, month without the need for a subsequent requestfurther requirement. Once This settlement of the final payment is made, it will shall be understood that regarded to all effects as due compliance by the SPONSOR’s SPONSOR of his financial obligations have concludedobligations. All payments must shall be made on submission upon the presentation of an invoice; the invoicecorresponding VAT shall be included as per current legislation at the time of payment, to which VAT will be added in accordance with the applicable law on the date it is issued on, in at the name of the SPONSOR or the ENTITY/PERSON IN CHARGE OF FINANCIAL ASPECTS (invoicing details) Nameonly legalized subsidiary in Spain). Invoices will be issued to the sponsor: CIF/VAT _________ (NOTE: Invoices will be issued to the sponsor, unless otherwise expressly stated that the invoices are issued to legalized sponsor linked subsidiary in Spain, whose data should be included in this clause). Invoices issued to the sponsor shall be provided by the following payer whose details are as follows: _________________ (NOTE: If you need to include an order number / Tax ID Number: Domicile / Registered Address: or purchase order invoices must indicate, and the procedure to be applied by the Foundation). Invoices will be sent for processing to the following e-mailaddress management: The SPONSOR/CRO must communicate by email to FIBHU12O the total amount that must be invoiced for the visits that have been made, detailing the breakdown of each of these visits and procedures detailed in the Economic Report (ANNEX_I). For this, must send an e-mail to xxxxxxxxxxx.xxxx@xxxxx.xxxxxx.xxx Payments ________ All payments to the FOUNDATION will Foundation shall be made by bank transfer, transfer (with charges payable bank fees being paid by the sender, payer) to: Holder/BeneficiaryName: Fundación para la Investigación Biomédica del Hospital Universitario 12 de octubre. BankGetafe Banking Entity: Caixabank, S.A. AddressBanco Santander Account number: Xxxxx xx xx Xxxxxxxxxx, 00 0x 000000049-Xxxxxx Account Nº/IBAN1982-21-2810000070 IBAN: XX00 0000 0000 0000 0000 0000 SWIFT CODE0000-0000-00-0000000000 SWIFT: CAIXE SBBxxx VAT number /Tax ID CODEXXXXXXXXXXX CIF: X-00000000 Payments made by the SPONSOR/CRO (choose as appropiate) to the FOUNDATION will be full settlements for the former, with the FOUNDATION being responsible for payment the amounts that, as appropriate, are payable to the TRIALS researchers. The PARTIES agree that, if the HOSPITAL lacks the necessary equipment for adequate performance of the TRIALS, the SPONSOR will provide the HOSPITAL with it, free-of-charge and assigning its use, either directly or via a third party. Furthermore, the SPONSOR will pay the cost, and arrange the supply, installation, maintenance, calibration and removal of the equipment, and training personnel in operating it, if necessary. The HOSPITAL, the FOUNDATION and the LEAD INVESTIGATOR will, in no case, be liable for its maintenance or its eventual loss. The equipment will consist of the following components: The Equipment will remain the property of the SPONSOR, or a third party, and will carry the relevant identification to show this. The Equipment may only be used to perform the TRIAL and, when it has ended, will be returned to the SPONSOR, or a third party, at no cost to the HOSPITAL or the FOUNDATION. When the LEAD INVESTIGATOR receives a request for return, they will make the Equipment available to the SPONSOR, or the third party appointed by it to collect it. On termination of the TRIALS, the SPONSOR may assign the Equipment to the HOSPITAL free-of-charge, for which purpose such documents as are necessary will be formalised. In the event that additional needs for equipment are detected during performance of the TRIALS, subsequent to the signature of this contract, the PARTIES must sign an addendum including the equipment made available, respecting the terms and conditions set out in the previous paragraphs.X-00000000
Appears in 1 contract
Samples: iisgetafe.es
FINANCIAL ASPECTS. The cost of this TRIAL has been initially budgeted at EUROS, not including VAT, __________EUROS (______€ ) (hereinafterTRIAL budget, from now on). This cost has been determined by applying a cost of _______ EUROS (____ €) per subject to be evaluated, as established by the Economic Memorandum of the TRIAL Budget), in accordance with the provisions of the Financial Memorandum for the TRIALS (Schedule IAnnex 1), which specifies all their financial economic aspects. This amount does not, in not cover or provide for any case whatsoever, include an obligation or inducement commitment for the HOSPITAL, the FOUNDATION, Foundation and/or the LEAD PRINCIPAL INVESTIGATOR to recommend, endorse, prescribe, buypurchase, use or arrange agree the use of any of the SPONSOR’s products. To request an invoiceThe study budget includes a unique payment, contact: xxxxxxxxxxx.xxxx@xxxxx.xxxxxx.xxx In additionregardless of the number of patients included in the trial., upon signature of this ONE THOUSAND EUROS (1.000€) for the Pharmacy Service and a unique payment of TWO THOUSAND EUROS (2.000 €) for management of the present contract, the SPONSOR/CRO (choose as appropriate) will pay the amount of 4,000/3,000 Euros, in a one-time, non-refundable payment, as administrative and contractual management costs. This payment will include expenses for CEIm evaluation, relevant amendments, contract management administration and addendum according to the contractestablished in the Study Budget (Annex I). This payment will include expenses for contract management administrative procedures and addendum to the contract. If the fiscal details of this invoice are different from those detailed for visitor invoices in clause 5.4., please indicate them below: Invoices will be issued to: Name: CIF/VAT number / Tax ID Number: Domicile / Registered Address: Invoices will be sent for processing to the following e-mail: The amount sum to be paid by the SPONSORSPONSOR/CRO (choose as appropiate) during performance during the implementation of the TRIALS will CLINICAL TRIAL shall be calculated by applying set according to the specifications of Schedule I 1, and must shall be paid to the FOUNDATION as detailed below: THREE THOUSAND EUROS (3.000€), non refundable, will be paid at contract signature, in the payments set out belowconcept of: A unique payment of ONE THOUSAND EUROS (1.000€), regardless of the number of patients included in the trial for the Pharmacy Service. A unique payment of TWO THOUSAND EUROS (2.000€) to the FOUNDATION, in concept of contract management. The TRIALS remainder of the CLINICAL TRIAL budget will shall be paid, at leastleast each semester, every six months in accordance with the details as detailed in the amounts table by of cost per visit and subject signed up recruited patient included in as Schedule I, 1 until the total amount cost of the Budget has been paidbudget is fully paid off. For that purpose, SPONSOR/CRO (choose as appropiate) The SPONSOR and the LEAD PRINCIPAL INVESTIGATOR will shall report to the FOUNDATION every six monthson a biyearly basis. These payments are instalments shall be considered as partial payments, subject to be payments on account, pending payment the settlement of the definitive final total expenses of the CLINICAL TRIAL. The final contribution of the SPONSOR for the TRIALS. The definitive total to implementation of the CLINICAL TRIAL shall be paid determined by the SPONSOR/CRO (choose as appropiate) for performing the TRIALS will be calculated based on the work effectively activities actually carried out to perform while conducting the TRIALS CLINICAL TRIAL (hereinafter, the Definitive Total‘Final cost’). The Definitive Total will Final cost shall be calculated estimated as follows: Within a maximum of three (3) months after termination from completion of the TRIALS TRIAL at the HOSPITAL, the SPONSOR/CRO (choose as appropiate) SPONSOR/CRO (choose as appropriate) and the LEAD PRINCIPAL INVESTIGATOR will notify shall report in writing to the FOUNDATION in writing of the total number of: of (1) subjects signed up recruited and assessedevaluated subjects, (2) visits effectively paidactual number of visits, (3) incidents occurringresulting incidents, and as well as (4) any tests, analyses, examinations, consultations or hospital test, analysis, exploration, appointment or stay stays of an extraordinary special nature which may that might have occurred, whether or not they are reflected included in the Financial Memorandum Schedule (Schedule I1). As soon as possible after the information referred to in of the previous paragraph point has been notified, the FOUNDATION will calculate, issue shall calculate and notify the SPONSORSPONSOR/CRO (choose as appropiate), in a the final invoice for the trials, the amount payment of the definitive total andCLINICAL TRIAL, as well as the outstanding sums, if necessary, claim the amounts pending paymentany, which must shall be paid within one (1) month, month without the need for a subsequent requestfurther requirement. Once This settlement of the final payment is made, it will shall be understood that regarded to all effects as due compliance by the SPONSOR’s SPONSOR of his financial obligations have concludedobligations. All payments must shall be made on submission upon the presentation of an invoice; the invoicecorresponding VAT shall be included as per current legislation at the time of payment, to which VAT will be added in accordance with the applicable law on the date it is issued on, in at the name of the SPONSOR or the ENTITY/PERSON IN CHARGE OF FINANCIAL ASPECTS (invoicing details) Nameonly legalized subsidiary in Spain). Invoices will be issued to the sponsor: CIF/VAT _________ (NOTE: Invoices will be issued to the sponsor, unless otherwise expressly stated that the invoices are issued to legalized sponsor linked subsidiary in Spain, whose data should be included in this clause). Invoices issued to the sponsor shall be provided by the following payer whose details are as follows: _________________ (NOTE: If you need to include an order number / Tax ID Number: Domicile / Registered Address: or purchase order invoices must indicate, and the procedure to be applied by the Foundation). Invoices will be sent for processing to the following e-mailaddress management: The SPONSOR/CRO must communicate by email to FIBHU12O the total amount that must be invoiced for the visits that have been made, detailing the breakdown of each of these visits and procedures detailed in the Economic Report (ANNEX_I). For this, must send an e-mail to xxxxxxxxxxx.xxxx@xxxxx.xxxxxx.xxx Payments ________ All payments to the FOUNDATION will Foundation shall be made by bank transfer, transfer (with charges payable bank fees being paid by the sender, payer) to: Holder/BeneficiaryName: Fundación para la Investigación Biomédica del Hospital Universitario 12 de octubre. BankXxxxxxxx Xxxxxxx Banking Entity: Caixabank, S.A. AddressBankia Account number: Xxxxx xx xx Xxxxxxxxxx, 00 0x 00000-Xxxxxx Account Nº/IBAN2038 1163 13 6000526076 IBAN: XX00 0000 0000 0000 0000 0000 SWIFT CODEES 86 2038 1163 13 6000526076 SWIFT: CAIXE SBBxxx VAT number /Tax ID CODECAHMESMMXXX CIF: X-00000000 Payments made by the SPONSOR/CRO (choose as appropiate) to the FOUNDATION will be full settlements for the former, with the FOUNDATION being responsible for payment the amounts that, as appropriate, are payable to the TRIALS researchers. The PARTIES agree that, if the HOSPITAL lacks the necessary equipment for adequate performance of the TRIALS, the SPONSOR will provide the HOSPITAL with it, free-of-charge and assigning its use, either directly or via a third party. Furthermore, the SPONSOR will pay the cost, and arrange the supply, installation, maintenance, calibration and removal of the equipment, and training personnel in operating it, if necessary. The HOSPITAL, the FOUNDATION and the LEAD INVESTIGATOR will, in no case, be liable for its maintenance or its eventual loss. The equipment will consist of the following components: The Equipment will remain the property of the SPONSOR, or a third party, and will carry the relevant identification to show this. The Equipment may only be used to perform the TRIAL and, when it has ended, will be returned to the SPONSOR, or a third party, at no cost to the HOSPITAL or the FOUNDATION. When the LEAD INVESTIGATOR receives a request for return, they will make the Equipment available to the SPONSOR, or the third party appointed by it to collect it. On termination of the TRIALS, the SPONSOR may assign the Equipment to the HOSPITAL free-of-charge, for which purpose such documents as are necessary will be formalised. In the event that additional needs for equipment are detected during performance of the TRIALS, subsequent to the signature of this contract, the PARTIES must sign an addendum including the equipment made available, respecting the terms and conditions set out in the previous paragraphs.X-00000000
Appears in 1 contract
Samples: www.iisgm.com
FINANCIAL ASPECTS. The cost of this TRIAL has been initially budgeted at EUROS, not including VAT, __________EUROS (______€ ) (hereinafterTRIAL budget, from now on) of which 78% was for the RESEARCH TEAM and 22% indirect costs for the FOUNDATION. This cost has been determined by applying a cost of _______ EUROS (____ €) per subject to be evaluated, as established by the Economic Memorandum of the TRIAL Budget), in accordance with the provisions of the Financial Memorandum for the TRIALS (Schedule IAnnex 1), which specifies all their financial economic aspects. This amount does not, in not cover or provide for any case whatsoever, include an obligation or inducement commitment for the HOSPITAL, the FOUNDATION, Foundation and/or the LEAD PRINCIPAL INVESTIGATOR to recommend, endorse, prescribe, buypurchase, use or arrange agree the use of any of the SPONSOR’s products. To request an invoice, contact: xxxxxxxxxxx.xxxx@xxxxx.xxxxxx.xxx In addition, upon signature The study budget includes a unique payment of this ____________________ (1.500 €) for management of the present contract, the SPONSOR/CRO (choose as appropriate) will pay the amount of 4,000/3,000 Euros, in a one-time, non-refundable payment, as administrative and contractual management costs. This payment will include expenses for CEIm evaluation, relevant amendments, contract management administration and addendum according to the contractestablished in the Study Budget (Annex I). This payment will include expenses for contract management administrative procedures and addendum to the contract. If the fiscal details of this invoice are different from those detailed for visitor invoices in clause 5.4., please indicate them below: Invoices will be issued to: Name: CIF/VAT number / Tax ID Number: Domicile / Registered Address: Invoices will be sent for processing to the following e-mail: The amount sum to be paid by the SPONSORSPONSOR/CRO (choose as appropiate) during performance during the implementation of the TRIALS will CLINICAL TRIAL shall be calculated by applying set according to the specifications of Schedule I 1, and must shall be paid to the FOUNDATION as detailed below: _______________ EUROS (1.500€), non refundable, will be paid at contract signature, in the payments set out below: concept of contract management. The TRIALS remainder of the CLINICAL TRIAL budget will shall be paid, at leastleast each semester, every six months in accordance with the details as detailed in the amounts table by of cost per visit and subject signed up recruited patient included in as Schedule I, 1 until the total amount cost of the Budget has been paidbudget is fully paid off. For that purpose, SPONSOR/CRO (choose as appropiate) The SPONSOR and the LEAD PRINCIPAL INVESTIGATOR will shall report to the FOUNDATION every six monthson a biyearly basis. These payments are instalments shall be considered as partial payments, subject to be payments on account, pending payment the settlement of the definitive final total expenses of the CLINICAL TRIAL. The final contribution of the SPONSOR for the TRIALS. The definitive total to implementation of the CLINICAL TRIAL shall be paid determined by the SPONSOR/CRO (choose as appropiate) for performing the TRIALS will be calculated based on the work effectively activities actually carried out to perform while conducting the TRIALS CLINICAL TRIAL (hereinafter, the Definitive Total‘Final cost’). The Definitive Total will Final cost shall be calculated estimated as follows: Within a maximum of three (3) months after termination from completion of the TRIALS TRIAL at the HOSPITAL, the SPONSOR/CRO (choose as appropiate) SPONSOR/CRO (choose as appropriate) and the LEAD PRINCIPAL INVESTIGATOR will notify shall report in writing to the FOUNDATION in writing of the total number of: of (1) subjects signed up recruited and assessedevaluated subjects, (2) visits effectively paidactual number of visits, (3) incidents occurringresulting incidents, and as well as (4) any tests, analyses, examinations, consultations or hospital test, analysis, exploration, appointment or stay stays of an extraordinary special nature which may that might have occurred, whether or not they are reflected included in the Financial Memorandum Schedule (Schedule I1). As soon as possible after the information referred to in of the previous paragraph point has been notified, the FOUNDATION will calculate, issue shall calculate and notify the SPONSORSPONSOR/CRO (choose as appropiate), in a the final invoice for the trials, the amount payment of the definitive total andCLINICAL TRIAL, as well as the outstanding sums, if necessary, claim the amounts pending paymentany, which must shall be paid within one (1) month, month without the need for a subsequent requestfurther requirement. Once This settlement of the final payment is made, it will shall be understood that regarded to all effects as due compliance by the SPONSOR’s SPONSOR of his financial obligations have concludedobligations. All payments must shall be made on submission upon the presentation of an invoice; the invoicecorresponding VAT shall be included as per current legislation at the time of payment, to which VAT will be added in accordance with the applicable law on the date it is issued on, in at the name of the SPONSOR or the ENTITY/PERSON IN CHARGE OF FINANCIAL ASPECTS (invoicing details) Nameonly legalized subsidiary in Spain). Invoices will be issued to the sponsor: CIF/VAT _________ (NOTE: Invoices will be issued to the sponsor, unless otherwise expressly stated that the invoices are issued to legalized sponsor linked subsidiary in Spain, whose data should be included in this clause). Invoices issued to the sponsor shall be provided by the following payer whose details are as follows: _________________ (NOTE: If you need to include an order number / Tax ID Number: Domicile / Registered Address: or purchase order invoices must indicate, and the procedure to be applied by the Foundation). Invoices will be sent for processing to the following e-mailaddress management: The SPONSOR/CRO must communicate by email to FIBHU12O the total amount that must be invoiced for the visits that have been made, detailing the breakdown of each of these visits and procedures detailed in the Economic Report (ANNEX_I). For this, must send an e-mail to xxxxxxxxxxx.xxxx@xxxxx.xxxxxx.xxx Payments ________ All payments to the FOUNDATION will Foundation shall be made by bank transfer, transfer (with charges payable bank fees being paid by the sender, payer) to: Holder/BeneficiaryName: Fundación para la Investigación Biomédica del Hospital Universitario 12 de octubre. BankGetafe Banking Entity: Caixabank, S.A. AddressBanco Santander Account number: Xxxxx xx xx Xxxxxxxxxx, 00 0x 000000049-Xxxxxx Account Nº/IBAN1982-21-2810000070 IBAN: XX00 0000 0000 0000 0000 0000 SWIFT CODE0000-0000-00-0000000000 SWIFT: CAIXE SBBxxx VAT number /Tax ID CODEXXXXXXXXXXX CIF: X-00000000 Payments made by the SPONSOR/CRO (choose as appropiate) to the FOUNDATION will be full settlements for the former, with the FOUNDATION being responsible for payment the amounts that, as appropriate, are payable to the TRIALS researchers. The PARTIES agree that, if the HOSPITAL lacks the necessary equipment for adequate performance of the TRIALS, the SPONSOR will provide the HOSPITAL with it, free-of-charge and assigning its use, either directly or via a third party. Furthermore, the SPONSOR will pay the cost, and arrange the supply, installation, maintenance, calibration and removal of the equipment, and training personnel in operating it, if necessary. The HOSPITAL, the FOUNDATION and the LEAD INVESTIGATOR will, in no case, be liable for its maintenance or its eventual loss. The equipment will consist of the following components: The Equipment will remain the property of the SPONSOR, or a third party, and will carry the relevant identification to show this. The Equipment may only be used to perform the TRIAL and, when it has ended, will be returned to the SPONSOR, or a third party, at no cost to the HOSPITAL or the FOUNDATION. When the LEAD INVESTIGATOR receives a request for return, they will make the Equipment available to the SPONSOR, or the third party appointed by it to collect it. On termination of the TRIALS, the SPONSOR may assign the Equipment to the HOSPITAL free-of-charge, for which purpose such documents as are necessary will be formalised. In the event that additional needs for equipment are detected during performance of the TRIALS, subsequent to the signature of this contract, the PARTIES must sign an addendum including the equipment made available, respecting the terms and conditions set out in the previous paragraphs.G-83728024
Appears in 1 contract
Samples: iisgetafe.es
